Evotec SE ADR (EVO)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
EVO
Evotec SE ADR
$1.32
-8.97%
HEALTHCARE · Cap: $600.61M
TAK
Takeda Pharmaceutical Co Ltd ADR
$21.77
+1.68%
HEALTHCARE · Cap: $68.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 653261% more annual revenue ($4.69T vs $718.32M). TAK leads profitability with a 0.9% profit margin vs -25.2%. TAK appears more attractively valued with a PEG of 0.48. TAK earns a higher WallStSmart Score of 54/100 (C-).
EVO
Hold42
out of 100
Grade: D
TAK
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.5%
Fair Value
$33.26
Current Price
$1.32
$31.94 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Reasonable price relative to book value
Generating 212.6B in free cash flow
Large-cap with strong market position
Areas to Watch
0.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -28.6% — below average capital efficiency
ROE of 5.2% — below average capital efficiency
0.9% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EVO
The strongest argument for EVO centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bear Case : EVO
The primary concerns for EVO are Revenue Growth, EPS Growth, Market Cap.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 305.9x leaves little room for execution misses. Thin 0.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
EVO profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.31 — expect wider price swings.
TAK is growing revenue faster at 6.7% — sustainability is the question.
TAK generates stronger free cash flow (212.6B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (54/100 vs 42/100). EVO offers better value entry with a 89.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology company headquartered in Hamburg, Germany, specializing in delivering comprehensive drug discovery and development solutions to the pharmaceutical and biotech industries. The firm is distinguished by its collaborative strategy, forming partnerships with leading pharmaceutical entities and prestigious academic institutions to accelerate the progress of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline, Evotec is strategically positioned to leverage new opportunities within the biopharmaceutical sector, reaffirming its essential contribution to healthcare innovation and improved patient outcomes.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?